C75-trans-racemic-C75-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁
C75-trans-racemic-C75-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁
C75-trans-racemic-C75-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁
C75-trans-racemic-C75-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEC75 transCat. No.: HY-12364ACAS No.: 191282-48-1Synonyms: ()-C75分式: CHO分量: 254.32作靶點: Fatty Acid Synthase (FAS)作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO :

2、83.3 mg/mL (327.54 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.9321 mL 19.6603 mL 39.3205 mL5 mM 0.7864 mL 3.9321 mL 7.8641 mL10 mM 0.3932 mL 1.9660 mL 3.9321 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥吻宓膬湟?,再依次添加助溶?為保證實驗

3、結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (9.83 mM); Suspended solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (9.83 mM); Clear solution3. 請依序添加每種溶劑: 10% DMSO 9

4、0% corn oil1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (9.83 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 C75 trans是C75的對映異構(gòu)體,C75是脂肪酸合成酶 (FASN) 的抑制劑。IC50 & Target IC50: 35 M (PC3 cell) 1體外研究 C75 inhibits PC3 cell growht with an IC50 of 35 M at 24 h. C75 (10-50 M) also reduces

5、 the growth ofLNCaP spheroids in a concentration-dependent manner with an IC50 of 50 M 1. (-)-C75 inhibits FASactivity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. (+)-C75 inhibitsCPT1 and its administration produces anorexia, suggesting that central inhibition

6、 of CPT1 is essential for theanorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potentialnew specific drugs for cancer and obesity 2.體內(nèi)研究 C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA),and pa

7、raventricular nucleus (PVN) 1024 h after i.p. injection. Intraperitoneal administration of C75 at 30mg/kg body weight inhibits food intake of mice by 95% within 2 h after i.p. injection 3. C75-treated DIOmice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty

8、acidoxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increasesfatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevatedconcentrations of malonyl-CoA 4.PROTOCOLCell Assay 1 Cells are seeded in 96-well plates and incub

9、ated for 2 days to allow exponential phase growth. Cells are thenished twice with PBS and treated with C75. After 24 or 48 h incubation, MTT is added to a final concentrationof 0.5 mg/ml and cultures are incubated for 2 h. Cells are then solubilized with DMSO before measuringabsorbance at 570 nm. Ce

10、ll growth is also measured, using MTT assay, every 24 h up to 96 h 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice: C75 is administered either by i.p. (i.p.; 30 mg/kg of body weight) or i.c.v. (10 g in 3 L of RPMIAdministration 3 medium 16

11、40) injection. One, 11.5, and 24 h after i.p. injection, cumulative food intake is measured, mice arekilled, brains are sectioned, and slices are subjected to immunohistochemical staining for c-Fos. All i.p.injections are given 1 h before the start of the dark cycle. For i.c.v. injection, mice are a

12、nesthetized withmetofane and given 3 l of RPMI medium 1640 (control) or C75 in RPMI medium 1640 into the lateralventricle with a calibrated 10-l Hamilton syringe 3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Rae C, et al. Inhibition of

13、Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE2. Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 hasantitumor activity. Chirality. 2013 May;25(5):2

14、81-7.3. Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc NatlAcad Sci U S A. 2003 May 13;100(10):5628-33.4. Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A.2002 Jul 9;99(14

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論